Abion Announces Phase 1 Clinical Trial Results of Solid Tumor Anticancer Drug at ASCO in the US

[Asia Economy Reporter Lee Gwan-joo] ABION announced on the 7th that it presented the results of the Phase 1 clinical trial of the solid tumor anticancer drug 'ABN401' at the American Society of Clinical Oncology (ASCO) held in Chicago, USA.

ABN401 is a solid tumor treatment targeting the hepatocyte growth factor receptor (c-MET). c-MET is a protein expressed by the MET (epithelial-mesenchymal transition) gene and is involved in cancer initiation and metastasis. It has been proven to be associated with the occurrence of various solid tumors such as lung cancer, stomach cancer, liver cancer, and colorectal cancer, and it is a highly promising anticancer biomarker for overcoming resistance to existing treatments.

In the Phase 1 clinical trial of ABN401, ABION verified safety and efficacy and determined the appropriate dosage for Phase 2. The dose escalation study from 50 mg to 1200 mg confirmed excellent drug safety with no drug-related adverse reactions of grade 3 or higher. Regarding efficacy, two cases of partial response (PR) were secured. Furthermore, the efficacy (PR) was maintained for up to 19 months of treatment, and no drug accumulation was observed in the body.

ABION is currently conducting seamless global Phase 1/2 clinical trials integrating Phase 1 and 2 for ABN401. Phase 1 trials were completed last year in Australia and Korea, and the final clinical study report (CSR) for Phase 1 was received from the CRO last month. An ABION official stated, “We confirmed that ABN401 has superior drug tolerability compared to competing drugs and a wide therapeutic window, making combination trials with other drugs advantageous,” adding, “We will accelerate technology licensing to global pharmaceutical companies.”

This content was produced with the assistance of AI translation services.